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MaBACKGROUND Vascular endothelial growth factor (VEGF)-B activates cytoprotective/antiapoptotic and minimally
angiogenic mechanisms via VEGF receptors. Therefore, VEGF-B might be an ideal candidate for the treatment of dilated
cardiomyopathy, which displays modest microvascular rarefaction and increased rate of apoptosis.
OBJECTIVES This study evaluated VEGF-B gene therapy in a canine model of tachypacing-induced dilated
cardiomyopathy.
METHODS Chronically instrumented dogs underwent cardiac tachypacing for 28 days. Adeno-associated virus serotype
9 viral vectors carrying VEGF-B167 genes were infused intracoronarily at the beginning of the pacing protocol or during
compensated heart failure. Moreover, we tested a novel VEGF-B167 transgene controlled by the atrial natriuretic factor
promoter.
RESULTS Compared with control subjects, VEGF-B167 markedly preserved diastolic and contractile function and
attenuated ventricular chamber remodeling, halting the progression from compensated to decompensated heart failure.
Atrial natriuretic factor–VEGF-B167 expression was low in normally functioning hearts and stimulated by cardiac pacing; it
thus functioned as an ideal therapeutic transgene, active only under pathological conditions.
CONCLUSIONS Our results, obtained with a standard technique of interventional cardiology in a clinically relevant
animal model, support VEGF-B167 gene transfer as an affordable and effective new therapy for nonischemic heart failure.
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ABBR EV I A T I ON S
AND ACRONYMS
AAV = adeno-associated virus
serotype 9
ANF = atrial natriuretic factor/
protein
CMV = cytomegalovirus
DCM = dilated cardiomyopathy
GFP = green ﬂuorescent
protein
HF = heart failure
LV = left ventricular
LVEDP = left ventricular
end-diastolic pressure
NOX2 = nicotinamide adenine
dinucleotide phosphate oxidase
VEGF = vascular endothelial
growth factor
VEGFR-1 = vascular
endothelial growth factor
receptor-1
VEGFR-2 = vascular
endothelial growth factor
receptor-2
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140Investigators have proposed various car-
diac gene therapy strategies, depending on
the target enzyme or structural protein they
deem to be critically involved in compensa-
tory or maladaptive cellular alterations. Over
the past 5 years, we and others have shown
the beneﬁcial effects of vascular endothelial
growth factor (VEGF)-B gene transfer in
experimental models of cardiac injury (5–7).SEE PAGE 166VEGF-B, 1 of the 5 members of the mammalian
VEGF family, is a major pro-survival (rather
than pro-angiogenic) factor (8). It selectively
binds vascular endothelial growth factor
receptor (VEGFR)-1, whereas the more exten-
sively studied pro-angiogenic VEGF-A binds
both VEGFR-1 and vascular endothelial growth
factor receptor-2 (VEGFR-2). The marked cyto-
protective/antiapoptotic (9) and minimally
angiogenic action of VEGF-B renders it
particularly well suited for gene therapy of
nonischemic dilated cardiomyopathy (DCM),a severe pathological condition not caused by coronary
artery disease in which the increased rate of apoptosis
seems to play a major role (10–12). Unfortunately, no
speciﬁc antiapoptotic pharmacological agents are
currently available to clinicians.
Although DCM occurs much less frequently than
ischemic disease, it remains largely untreatable and is
responsible for most U.S. cardiac transplants (13).
VEGF-B–based cytoprotective therapy might prove
successful in the ﬁght against this severe patho-
logical condition. Therefore, the goal of the present
study was to: 1) validate a clinically applicable car-
dioselective VEGF-B gene therapy in a large animal
model of DCM; 2) test the efﬁcacy of a safer approach
on the basis of inducible VEGF-B transgenes turned on
and off in response to, respectively, the occurrence or
remission of the pathological condition; and 3) test the
hypothesis that VEGFR-1 is the principal mediator of
the cytoprotective action exerted by VEGFs. We
delivered VEGF-B167, the prevalent VEGF-B isoform
(14), in canine tachypacing-induced HF. This is the
best-characterized model of DCM, reproducing
numerous pathophysiological and molecular alter-
ations of the human disease (7,15–17). Parallel experi-
ments were conducted in cultured cardiomyocytes.
METHODS
Fifty-three adult male, mongrel dogs (22 to 25 kg body
weight) were chronically instrumented as previously
described (Online Appendix) (7,17,18). The dogswere randomly divided into 5 experimental groups
(Figure 1). Transgenes were encapsidated into adeno-
associated virus serotype 9 (AAV9, henceforth indi-
cated as AAV) and infused in the left coronary artery
(anterior descending þ circumﬂex branches) in 4
groups. Ten chronically instrumented dogs did not
receive AAV. Intracoronary AAV delivery was per-
formed 10 to 15 days after the surgical procedure or
after 2 weeks of pacing. Dogs were lightly anes-
thetized (10 to 20 mg/kg of pentobarbital intrave-
nously); after local anesthesia, a 5-F sheath was
inserted percutaneously into the right femoral artery
for coronary catheterization. Left circumﬂex and
anterior descending coronary arteries were selec-
tively and alternatively catheterized by using a 2.5-F
microinfusion catheter to infuse 20 ml of AAV sus-
pension (1  1013 to 5  1013 viral particles) in normal
phosphate-buffered solution containing 3 ng/kg of
adenosine and 5 ng/kg of substance P. The AAV
suspension was administered slowly over 20 min
followed by 10 min of intracoronary infusion of
physiological saline solution. Simultaneously with
AAV intracoronary delivery, 1 mg/kg/min of nitro-
glycerin was infused intravenously. Adenosine, sub-
stance P, and nitroglycerin were used to increase
permeability in myocardial capillaries. Hemodynamic
parameters were recorded during this procedure until
full post-anesthesia recovery.
To induce HF, dogs were subjected to left ventric-
ular (LV) pacing with an external pacemaker set at
210 beats/min for 3 weeks; the pacing rate was
increased to 240 beats/min for an additional week. On
the basis of our previous studies (17,18), this pacing
protocol causes DCM and compensated HF during the
ﬁrst 3 weeks, culminating in severe HF at 27 to 30
days. All of the dogs were killed at 28 days to compare
in vivo and ex vivo data at a ﬁxed time point.
The protocol was approved by the Institutional
Animal Care and Use Committee of Temple Univer-
sity, and it conformed to the guiding principles for
the care and use of laboratory animals published by
the National Institutes of Health.
Histological and polymerase chain reaction anal-
ysis of cardiac tissue was performed as previously
described by us (Online Appendix) (6,7,19,20).
To determine cytoprotective effects of VEGF-B167,
neonatal rat cardiomyocytes were isolated and
cultured with production of reactive oxygen species
measured as previously described (19,21,22). They
were exposed to VEGF-B167, VEGF-A, VEGF-E, and
placental growth factor in the absence or in the
presence of angiotensin II or norepinephrine (50 M–6).
STATISTICAL ANALYSIS. Data are presented as mean
 SEM. Statistical analysis was performed with
FIGURE 1 Experimental Groupings
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Transgenes were encapsidated into adeno-associated virus serotype 9 (AAV) and infused in the left coronary artery (anterior descending þ
circumﬂex branches) in randomized groups of dogs. ANF ¼ atrial natriuretic factor promoter; CMV ¼ cytomegalovirus promoter;
eGFP ¼ enhanced green ﬂuorescent protein; VEGF ¼ vascular endothelial growth factor.
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141commercially available software (IBM SPSS Statistics,
IBM Corporation, Armonk, New York). Hemody-
namic, cardiac functional, histological, and molecular
changes at different time points were compared by
using 1-way analysis of variance for repeatedmeasures
and comparisons between groups by 2-way analysis of
variance, in both cases followed by the Student-
Newman-Keuls post-hoc test. When samples were not
normally distributed, a nonparametric test was used,
and data are presented as box plots. For all statistical
analyses, signiﬁcance was accepted at p < 0.05.
RESULTS
Intracoronary gene delivery was hemodynamically
well tolerated. Co-infusion of vasodilators such as
adenosine, nitroglycerin, and substance P during
intracoronary AAV delivery caused the following
reversible changes (Figure 2): increased coronary
blood ﬂow, decreased systolic pressure (w20 mm Hg),
and altered LV pressure waveform shape during the
diastolic phase, reﬂected by decreased dP/dtmin
(minimal ﬁrst derivate of LV pressure). Left atrial
pressure was not affected.
Mouse VEGF-B167 (henceforth indicated as VEGF-B)
gene or the green ﬂuorescent protein (GFP) reportergene, both controlled by the constitutively active
cytomegalovirus (CMV) promoter, were delivered to
2 groups (Figure 1). One group received 1  1013 AAV–
CMV–GFP (used as control group), and the other
group received 2  1013 AAV–CMV–VEGF-B. AAV
administered 2 days before starting the pacing pro-
tocol allowed time for transgene expression, which
typically takes w10 days when carried by this type of
viral vector (3). To eliminate the possibility that
early gene transfer could have exerted a pre-
emptive action, 1 group of dogs received 2  1013
AAV–CMV–VEGF-B in the left coronary artery
after 2 weeks of pacing, at a stage of compensated
HF, thus simulating a more realistic clinical scenario.
All the functional measurements were acquired
at a spontaneous heart rate, with the pacemaker
turned off.
Dogs transduced with GFP displayed the typical
progressive deterioration of hemodynamic parame-
ters over 4 weeks (Figure 3), as previously described
(17,18); this time course was not signiﬁcantly
different compared with that in nontransduced dogs
undergoing cardiac pacing (Online Figure 1). At 28
days, left ventricular end-diastolic pressure (LVEDP)
increased to w25 mm Hg, indicating congestive,
decompensated HF. Conversely, cardiac transduction
FIGURE 2 Minor Hemodynamic Changes During Intracoronary AAV Delivery
Baseline 12 min AAV Infusion
Time (sec)
LVP
dP/dtmax
AoP
CBF
LAP
45 min post-AAV Infusion
Representative hemodynamic tracings simultaneously recorded through chronically implanted probes and catheters before, during, and after AAV intracoronary delivery.
The scale was automatically adjusted by the acquisition system and differs in the 3 panels. AAV ¼ adeno-associated virus serotype 9; AoP ¼ aortic pressure (with pressure
average value); CBF ¼ blood ﬂow in the circumﬂex coronary artery (with ﬂow average value); dP/dt ¼ ﬁrst derivative of left ventricular pressure (with dP/dtmax average
value); LAP ¼ left atrial pressure (with pressure average value); LVP ¼ left ventricular pressure (with systolic pressure average value).
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142with VEGF-B markedly attenuated the hemodynamic
derangement. The most notable effect was no signif-
icant change during the entire pacing period in
LVEDP in those dogs transduced early; in the delayed
transduction group, further increases were prevented
after the second week. LV systolic pressure, mean
arterial pressure, and dP/dtmax (maximal ﬁrst deriv-
ative of LV pressure), although signiﬁcantly
decreased after 2 weeks of pacing compared with
baseline, displayed no further signiﬁcant decrease in
the 2 groups transduced with VEGF-B. Finally, coro-
nary blood ﬂow did not change signiﬁcantly over time
in any of the groups (Online Figure 2). Therefore,
compared with the control HF group, VEGF-B gene
delivery halted the transition from compensated to
decompensated HF, even in hearts with signiﬁcant
functional impairment.
A desirable strategy in gene therapy would be on
the basis of inducible transgenes turned on and off in
response to, respectively, the occurrence or remis-
sion of the pathological condition. We therefore
generated a construct consisting of the 5’-ﬂanking
region –638/62 of the rat atrial natriuretic factor
(ANF), which includes most of the ANF promoter and
enhancer, linked to the VEGF-B gene. Our goal was to
obtain VEGF-B expression only in response to intra-
cellular ANF inducers, adopting a previously vali-
dated strategy (23,24). ANF is expressed in failing but
not normal ventricles (25,26); therefore, VEGF-Bwould be expressed only during the development of
HF. We ﬁrst tested the responsiveness of the ANF 5’-
ﬂanking region –638/62 linked to GFP in a plasmid to
transfect cultured rat neonatal cardiomyocytes stim-
ulated with isoproterenol, a known ANF inducer (27)
(Online Figure 3). In response to isoproterenol, the
ANF element was able to drive approximately one-
third of the GFP expression found in cells trans-
fected with CMV-GFP. To compensate for the weaker
promoter in vivo, we delivered 5  1013 AAV carrying
ANF–VEGF-B in the left coronary artery of 15 dogs, 2
days before starting the pacing protocol (Figure 1). As
a control group, 5 of these dogs did not undergo
cardiac pacing and were killed 28 days later. Figure 4A
shows that LVEDP and dP/dtmax were signiﬁcantly
more altered compared with the AAV–CMV–VEGF-B
group; however, they remained within levels consis-
tent with moderate/compensated HF. Alternatively,
LV systolic and mean arterial pressures were not
signiﬁcantly different between the 2 groups. Non-
paced dogs did not show any signiﬁcant functional or
morphological changes over time (data not shown).
A peculiarity of tachypacing-induced HF is its
gradual functional recovery over a few weeks after
restoration of spontaneous heart rate (18,28). We
exploited this characteristic to test whether ANF–
VEGF-B gene expression was silenced after post-
failure recovery. In 5 of the 15 dogs transduced with
ANF–VEGF-B, the pacemaker was disconnected after
FIGURE 3 VEGF-B Gene Transfer Halts the Progression to Decompensated HF
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14328 days of pacing, the functional parameters were
monitored, and the animals were killed 2 weeks
later. As expected, these dogs’ hemodynamic values
returned to normal or quasi-normal values (Figure 4A).
We chose this time point, on the basis of a previous
study in a similar dog model, in which circulating
ANF was already normalized 1 week after turning off
the pacemaker (28). We found a marked and signif-
icant increase in median ANF gene expression
(normalized by the housekeeping gene hypoxan-
thine phosphoribosyl-transferase) in HF versus
normal LV tissue (0.86 [range 0.2 to 1.85] vs. 0.04
[range 0.03 to 0.06]). Similarly, ANF expression was
very low in hearts not subjected to pacing and
transduced with ANF–VEGF-B, although ANF–VEGF-B was mildly expressed in the left ventricle, likely
due to some degree of basal transcription, also
noticed in vitro (Online Figure 3).
However, ANF–VEGF-B transgene expression
markedly increased in LV tissue after 28 days of pacing,
consistent with pathological ANF up-regulation,
returning to almost control levels after post-pacing
functional recovery when ANF levels were normal-
ized (Figure 4B). Of note, ANF–VEGF-B gene expres-
sion in LV tissue was signiﬁcantly lower than CMV–
VEGF-B expression, which could partially explain the
difference between the effects of the 2 therapeutic
approaches on hemodynamics. Furthermore, hearts
transduced with CMV-VEGF displayed ANF levels not
signiﬁcantly different from nonpaced hearts.
FIGURE 4 ANF–VEGF-B: Inducible Therapeutic Transgene
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(A) Comparison between the main hemodynamic changes, over 4 weeks of chronic cardiac pacing, in dogs with intracoronary infusion of
AAV–CMV–VEGF-B or AAV–ANF–VEGF-B (n ¼ 10 per group). Five dogs receiving AAV–ANF–VEGF-B were observed for an additional 14-day
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day 14 within group; #p < 0.05 versus AAV–CMV–GFP at the same time point. (B) Gene expression of ANF, CMV–VEGF-B, and ANF–VEGF-B in
the left ventricle. Messenger ribonucleic acid (mRNA) was quantiﬁed as fold expression of the housekeeping gene hypoxanthine
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FIGURE 5 Cardiac Functional and Morphological Changes
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FIGURE 6 Histological Analysis
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(A) Immunohistochemical detection of GFP in cardiac tissue demonstrated heterogeneous transduction efﬁciency after intracoronary AAV
delivery. Representative photomicrographs from negative control group, left ventricle (LV) and right ventricle (RV); n¼ 5 per group. (B) VEGF-B
gene transfer attenuated myocardial apoptosis and prevented microvascular rarefaction. Nuclei are stained with 4’,6-diamidino-2-
phenylindole (DAPI), apoptotic nuclei identiﬁed by terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL), and cardiomyocytes
stained with a-sarcomeric actin (SA); n ¼ 5 per group. Microvascular density normalized by the number of cardiomyocyte ﬁbers; total
microvessel numbers were quantiﬁed by using immunoﬂuorescence staining for endothelial cells (lectin positive), whereas microvessels with
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146LV end-diastolic diameter increased by w25% and LV
end-diastolic thickness decreased by w30% after 28
days of pacing in hearts transduced with GFP, indi-
cating development of DCM (Figure 5A) (17,18,28,29).
The increase in diameter was signiﬁcantly attenuated
by AAV–CMV–VEGF-B as well as by AAV–ANF–VEGF-B
administration. Such a beneﬁcial effect was even
more pronounced on LV end-diastolic thickness.
Cardiac remodeling in control HF was associated with
>50% reduction in LV ejection fraction and >70%
reduction in LV systolic wall thickening, 2 commonlyused indexes of contractility. Cardiac transduction
with both CMV–VEGF-B and ANF–VEGF-B attenuated
these changes, although they remained signiﬁcant
versus baseline.
LV tachypacing causes dyssynchronous contrac-
tion, leading to an asymmetric contractile impair-
ment, more pronounced in the LV free wall compared
with the septum (30). In our experiments, AAV was
delivered intracoronarily, without targeting speciﬁc
regions of the heart. Therefore, we assessed whether
gene therapy was similarly beneﬁcial in the LV free
FIGURE 6 Continued
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147wall and septum. Echocardiography-based strain
analysis was used to assess maximal circumferential
shortening of the 2 opposite walls of the LV chamber.
We conﬁrmed the asymmetric functional impairment
in both LV sites, but circumferential shortening was
more preserved in hearts receiving the VEGF-B trans-
gene (Figure 5B). However, the best protective effect
in the septum occurred in hearts that received AAV–
CMV–VEGF-B at the beginning of the pacing protocol.
The signiﬁcant functional effects of VEGF-B gene
delivery indicated achievement of an adequate,
therapeutic level of myocardial transduction. By
localizing the reporter gene GFP expression with
immunohistochemistry in the control HF group,
we could precisely quantify the percent and topo-
graphic distribution of transduced cells after intra-
coronary gene delivery. In both the left and right
ventricles, transduction efﬁciency ranged widely
from a maximal value in the subendocardial layers ofthe myocardium to a minimal value in the sub-
epicardial layers (Figure 6A). Normal control, non-
transduced cardiac tissue was obtained from
chronically instrumented dogs killed for unrelated
studies. Overall, expression efﬁciency was higher in
the left ventricle versus the right ventricle.
Increased myocardial apoptosis is a known hall-
mark of human and experimental DCM (10–12,15).
Histochemical analysis indicated a reduced percent-
age of apoptotic cells after 28 days of pacing in hearts
transduced with CMV–VEGF-B or ANF–VEGF-B com-
pared with control HF (Figure 6B). Another character-
istic of DCM, the absence of major lesions of
large coronary arteries associated with myocardial
microvascular rarefaction (16), was conﬁrmed in our
canine HF model, and CMV–VEGF-B or ANF–VEGF-B
gene transfer preserved the density of capillaries and
smooth muscle actin–positive microvessels. Finally, the
number of T lymphocytes in the myocardium did not
FIGURE 7 VEGFR-1 Agonists Activate Antioxidant Defenses in Cardiomyocytes
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FIGURE 7 Continued
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Use of vascular endothelial growth factor receptor (VEGFR)-1 agonists to activate antioxidant defenses in cardiomyocytes is seen in (A) representative photomicrographs
and quantiﬁcation of superoxide detection by dihydroethidium (DHE) in cardiac tissue slices (n ¼ 3 per group); (B) representative images in angiotensin II (Ang II)–treated
cultured neonatal cardiomyocytes showing ﬂuorescence of MitoSOX (detecting mitochondrial superoxide) and 20,70-dichloroﬂuorescein diacetate (DCF; detecting
cytosolic H2O2 ) and relative quantiﬁcations in the bar graph (n ¼ 5 to 12 per group); and (C) representative images showing DCF ﬂuorescence in norepinephrine (NE)-
treated cultured neonatal cardiomyocyte and relative quantiﬁcations in the bar graph (n ¼ 5 to 12 per group). *p < 0.05 versus control group. †p < 0.05 vs NE.
#p < 0.05 vs Ang || þVEGF-B. arb. ¼ arbitrary; PlGF ¼ placental growth factor; other abbreviations as in Figures 1 and 2.
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149change signiﬁcantly in any of the transduced hearts
compared with nontransduced hearts after 28 days of
pacing (Online Figure 4).
VEGF-B ACTIVATES ANTIOXIDANT DEFENSES. Dihy-
droethidium staining of cross sections from freshly
harvested LV tissue and subsequent quantiﬁcation of
ﬂuorescence intensity (19) indicated increased reac-
tive oxygen species production in failing versus
normal hearts (Figure 7A). This production was
signiﬁcantly lower in tissue slices harvested from
paced hearts that had been transduced with VEGF-B.
We therefore performed experiments in cultured rat
neonatal cardiomyocytes to test whether: 1) VEGF-B
attenuates reactive oxygen species generation in
response to both angiotensin II and norepinephrine,
2 major promoters of oxidative stress (31,32); and 2)
these effects are speciﬁc of VEGFR-1 ligands or shared
by VEGFR-2 ligands. We compared VEGF-B with
placental growth factor (another selective VEGFR-1
ligand), VEGF-A (a ligand of both VEGFR-1 and
VEGFR-2) (8), and VEGF-E (a selective VEGFR-2ligand) (33). Figure 7B shows that increased mito-
chondrial superoxide and cytosolic H2O2 production,
detected, respectively, by MitoSOX red and
20,70-dichloroﬂuorescein diacetate, were signiﬁcantly
attenuated only by VEGF-B and placental growth
factor but not by equivalent concentrations of
VEGF-A and VEGF-E. However, norepinephrine-
induced cytosolic reactive oxygen species elevation
was attenuated in neonatal cardiomyocytes pre-
treated with VEGF-B but not placental growth factor,
VEGF-A, or VEGF-E (Figure 7C).
We next explored the most obvious mechanisms
potentially involved in the protection against angio-
tensin II, namely potentiation of mitochondrial su-
peroxide dismutase and inhibition of nicotinamide
adenine dinucleotide phosphate oxidase (NOX2).
Pre-treatment of cultured cardiomyocytes with short-
interfering ribonucleic acid against mitochondrial
superoxide dismutase enhanced the MitoSOX signal
in response to angiotensin II (Online Figure 5),
conﬁrming the importance of this enzyme as a
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150mitochondrial antioxidant defense. Importantly, the
anti–mitochondrial superoxide dismutase short-
interfering ribonucleic acid abrogated the beneﬁcial
effects of VEGF-B.
The activation of the isoform 2 of the superoxide-
generating enzyme NOX2 in response to angiotensin
II was tested by quantifying the translocation of the
enzyme subunit p47 to plasma membrane rafts, a
mandatory step for the assembling of this enzyme
complex. Angiotensin II caused a marked trans-
location of p47 to plasma membrane, as expected,
which was largely prevented by VEGF-B but not by
VEGF-A (Online Figure 5). However, VEGF-B did not
affect the NOX2 catalytic subunit gp91phox protein
expression (data not shown).
DISCUSSION
We previously provided proof of concept of the
beneﬁcial effects of the VEGF-B167 gene delivery by
direct intramyocardial injections in canine pacing-
induced HF, whereas VEFG-A was ineffective (7).
The present study successfully addresses remaining
important questions; that is, whether intracoronary
AAV–VEGF-B infusion (which is more realistic in
clinical practice) is similarly effective and whether
VEGFR-1 is the sole mediator of cardiomyocyte pro-
tection against oxidative stress.
Different from intramyocardial injections, intra-
vascular infusions are challenging because viral vec-
tors can be rapidly ﬂushed away from the target cells.
We found that intracoronary AAV–VEGF-B delivery,
conducted with procedures feasible at any coronary
catheterization unit, was well tolerated, and dis-
played marked therapeutic efﬁcacy halting progres-
sion toward decompensated HF (Central Illustration).
Hemodynamic alterations and cardiac remodeling
were blunted, if not completely prevented; consis-
tently, at tissue level, the rate of apoptosis (a major
DCM pathogenic determinant) was markedly
reduced. Of note, LVEDP, an index of central con-
gestion and diastolic dysfunction, remained within
the almost physiological range of 6 to 10 mm Hg even
after 28 days of tachypacing. Considering the severity
and the elevated cardiac stress characterizing this
model of HF, such results are promising.
Another important aspect was the equally high
therapeutic efﬁcacy of AAV–VEGF-B delivered to dogs
with compensated HF, corresponding to the stage
when most patients seek medical care for initial
symptoms. In those dogs, gene therapy prevented
further worsening of any functional alteration already
developed after 2 weeks of pacing. Such rapidly
occurring beneﬁcial effect suggests that VEGF-B–mediated cytoprotection may not be the only
mechanism involved. Other authors have found that
VEGFR-1 agonists stimulate contractility by en-
hancing cytosolic calcium ion transients in neonatal
ventricular myocytes (34); therefore, part of the
therapeutic action we found in dogs could be due to
direct support of contractile function. It is known that
myocardial VEGFR-1 is down-regulated in DCM,
whereas VEGF-B does not change signiﬁcantly (7,16).
Although intracoronary AAV infusion has been
previously used in several large animal and human
studies, to our knowledge, no detailed description of
myocardial transduction efﬁciency and regional het-
erogeneities was provided. We chose the serotype 9
AAV for its known cardiotropism (3,35). However, by
using the GFP reporter, we found that the trans-
duction efﬁciency was relatively high only in the
subendocardial layers of ventricular walls and mini-
mal in others. This ﬁnding was surprising; nonethe-
less, it supported the high efﬁcacy/transduction ratio
attained with AAV–VEGF-B. Conceivably, the action
of VEGF-B synthesized in transduced cells extended
to remote cells in a paracrine fashion.
Dogs with sustained VEGF-B expression were
observed for a maximal period of 6 weeks. During that
time, we detected no clinical or functional change
indicative of harmful adverse effects; cardiac tissue
analysis did not reveal speciﬁc alterations, including
a possible increase in T lymphocyte inﬁltration. We
did not expect any, as other authors found only
moderate morphological changes and no functional
alterations in transgenic mice with cardiac-speciﬁc
VEGF-B overexpression (36). However, deﬁnitive
conclusions about adverse effects will require long-
term monitoring of dogs transduced with VEGF-B
because this factor has also been implicated in path-
ological processes (37). Thus, an important ﬁnding of
the present study is the curative efﬁcacy achieved
with very mild, hence theoretically safe, myocardial
transduction. Moreover, we tested the inducible
transgene strategy, which renders unnecessary the
CMV promoter, further reducing possible risks related
to long-term expression. Ideally, therapeutic trans-
genes should be induced by pathological molecular
changes and silenced when the curative effect has
been achieved. Although this strategy is not novel
(38,39), it has not been previously applied to cardiac
gene therapy in large animal models. The present
results are encouraging because, similar to ANF, ANF–
VEGF-B expression increased in response to chronic
pacing and proved, at least in part, to be therapeuti-
cally efﬁcacious. The reversibility of transgene
expression was indicated by the return of ANF–VEGF-
B messenger ribonucleic acid to low control levels
CENTRAL ILLUSTRATION VEGF-B167 Gene Therapy in Dilated Cardiomyopathy
Woitek, F. et al. J Am Coll Cardiol. 2015; 66(2):139–53.
Intracoronary infusion of adeno-associated virus serotype 9 (AAV)–vascular endothelial growth factor (VEGF)-B delays development of pacing-induced heart failure.
A putative cardioprotective mechanism is inhibition of reactive oxygen species (ROS) production, which, in turn would prevent apoptotic cell death (upper panel).
This and other potential mechanisms preserve cardiac function in the VEGF-B–treated group compared with the green ﬂuorescent protein (GFP) control group as
indicated, for instance, by the left ventricular end-diastolic pressure (LVEDP) and left ventricular end-diastolic diameter (LVEDD), as well as by the higher dP/dtmax and
left ventricular ejection fraction (LVEF) (bottom panel). CMV ¼ cytomegalovirus promoter.
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151after post-pacing recovery, mirroring LV ANF
normalization. Additional testing will help reﬁne this
strategy and maximize its efﬁcacy.
CYTOPROTECTIVE MECHANISMS. Oxidative stress is
increased in HF and has been proposed as a primary
pathogenic factor responsible for progressive cardiac
tissue damage (31,32,40–43). Angiotensin II and
norepinephrine, 2 mediators whose production/
release is abnormally up-regulated in failing hearts,
promote oxidative stress by activating NOX2 (31) and
feeding the H2O2-generating enzyme monoamine
oxidase (32). The present novel ﬁnding is that only
the selective VEGFR-1 ligands VEGF-B and placental
growth factor prevented mitochondrial superoxide
and cytosolic H2O2 overproduction in cultured
neonatal cardiomyocytes exposed to angiotensin II.VEGF-A, a dual VEGFR-1 and VEGFR-2 ligand, exerted
a smaller, nonsigniﬁcant effect, whereas VEGF-E, a
selective VEGFR-2 ligand, was ineffective. We further
showed, for the ﬁrst time, that VEGF-B (but not the
other members of the VEGF family) could mitigate
H2O2 overproduction in cultured cardiomyocytes
exposed to norepinephrine. These results strongly
suggest that an important mechanism underlying the
therapeutic action of VEGF-B in vivo might consist of
antagonizing the pro-oxidant effects of angiotensin II
and norepinephrine.
Our data also suggest that antioxidant effects are
exerted only by the VEGFR-1 ligands of the VEGF
family, which perhaps can explain why, in our pre-
vious study, VEGF-A gene transfer did not prove
beneﬁcial in tachypacing-induced HF (7). Redox
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Pharmacological options for the treatment of patients
with DCM are currently limited, but gene delivery of
VEGF-B can activate cytoprotective mechanisms in
myocardium and was efﬁcacious in a pre-clinical
model of this disease state.
TRANSLATIONAL OUTLOOK: Further research
involving large animals are needed to more fully eval-
uate the potential of therapy with transgenes and us-
ing various viral vectors and modalities of delivery for
the treatment of DCM and other myocardial disorders.
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152equilibrium is ﬁnely regulated by a conspicuous
number of pro-oxidant and antioxidant enzymes.
However, in view of future investigations, we focused
on 2 major enzymes: mitochondrial superoxide dis-
mutase, a mitochondrial defense against superoxide
generation, and NOX2, the superoxide-generating
enzyme activated by angiotensin II. The excess
mitochondrial superoxide production in cells ex-
posed to angiotensin II could not be prevented by
VEGF-B when mitochondrial superoxide dismutase
overexpression was prevented by a speciﬁc short-
interfering ribonucleic acid, indicating this enzyme’s
important involvement. Moreover, VEGF-B blocked
the activation of NOX2. We tested these mechanisms
in cardiomyocytes, but we cannot exclude the possi-
bility that the protective action of VEGF-B in the
intact heart beneﬁts other important cell types such
as endothelium and ﬁbroblasts.
STUDY LIMITATIONS. First, due to the characteristics
of our dog model, we could only test the therapeutic
effects of VEGF-B gene transfer over a relatively short
period, whereas human chronic HF develops over
many years. Second, as conducted by other authors,
our in vitro studies were performed in neonatal car-
diomyocytes because, compared with adult cardio-
myocytes, they are easier to obtain in large quantities
for numerous experiments and to be stablymaintained
in culture for days without undergoing degenerative
processes. However, some additional tests were per-
formed in isolated adult cardiomyocytes, and we
found similar responses to angiotensin II and VEGF-B,
supporting the reliability of our results in neonatal
cardiomyocytes (Online Figure 6). Finally, our exper-
iments aimed at identifying molecular mechanisms
responsible for the protective effects of VEGFR-1
ligands against oxidative stress are preliminary and
warrant more in-depth studies at the cellular level.CONCLUSIONS
In this pre-clinical model, VEGF-B gene transfer
emerged as an efﬁcacious and safe therapy for DCM.
The perspective of blocking with a single intracoro-
nary infusion, at early stages of HF, the malignant
evolution of cellular/molecular processes otherwise
hardly delayed by chronic polypharmacological treat-
ments is appealing.
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